Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Nvs crawled time : 07:00 save search
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
Published: 2024-03-04 (Crawled : 07:00) - globenewswire.com
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: -0.6%
H: 0.68%
C: 0.51%
children novartis
USD 1.02 billion growth in Gastrointestinal Stromal Tumors Therapeutics (GIST) Market, Increasing awareness campaigns about GIST boosting the growth, 17000 + Technavio
Published: 2024-01-25 (Crawled : 07:00) - prnewswire.com
NVSEF | $93.6375 -0.49% 6.88% 130
|
Health Technology
|
| O: -3.67%
H: 0.0%
C: 0.0%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: -0.44%
H: 0.19%
C: -0.08%
tumors gastrointestinal therapeutics growth
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
Published: 2024-01-08 (Crawled : 07:00) - globenewswire.com
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 0.89%
H: 0.12%
C: -0.17%
scemblix leukemia trial response molecular
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
Published: 2023-12-11 (Crawled : 07:00) - globenewswire.com
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 0.75%
H: 0.55%
C: 0.27%
novartis study
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
Published: 2023-11-20 (Crawled : 07:00) - globenewswire.com
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: -0.18%
H: 0.88%
C: 0.54%
kisqali sabcs novartis
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
Published: 2023-10-30 (Crawled : 07:00) - globenewswire.com
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 1.69%
H: 0.25%
C: -0.07%
nephropathy novartis study
Oncology market size in India to grow by USD 947.84 million between 2022 and 2027; Growth driven by increased prevalence of cancer - Technavio
Published: 2023-05-02 (Crawled : 07:00) - prnewswire.com
AZNCF | $135.94 -2.12% -4.19% 770
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: -0.44%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: -0.57%
H: 1.69%
C: 1.55%
MDT | $80.23 0.13% -0.05% 7.5M
|
Health Technology
|
| O: -0.53%
H: 0.88%
C: 0.03%
BAX | $40.04 -0.72% -0.82% 3.1M
|
Health Technology
|
| O: -0.4%
H: 0.81%
C: -0.38%
ABT | $108.89 -0.2% 0.28% 3.4M
|
Health Technology
|
| O: -0.05%
H: 0.79%
C: 0.4%
AZN | $68.73 -0.29% -0.26% 7.1M
|
Health Technology
|
| O: -0.71%
H: 1.09%
C: 0.99%
GOOGL | $154.86 -1.82% -2.08% 21M
|
Technology Services
|
| O: -0.06%
H: 0.06%
C: -1.7%
GOOG | $156.33 -1.8% -1.83% 17M
|
Technology Services
|
| O: -0.05%
H: 0.07%
C: -1.56%
india cancer growth market
Pulmonary arterial hypertension (PAH) drugs market size to grow by USD 2,080.07 million between 2022 and 2027; Growth driven by growing prevalence of PAH - Technavio
Published: 2023-04-18 (Crawled : 07:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 510
|
Health Technology
|
| O: -6.76%
H: 3.18%
C: 1.34%
AZNCF | $135.94 -2.12% -4.19% 770
|
Health Technology
|
| O: 2.33%
H: 0.7%
C: -0.88%
AVTE M | $25.3 0.24% 0.43% 110K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 2.26%
C: 1.38%
VTRS | $11.32 -0.09% -0.09% 3.6M
|
Health Technology
|
| O: 0.2%
H: 0.09%
C: -0.5%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 0.18%
H: 0.11%
C: -0.85%
GSK | $40.5 -0.39% -1.09% 2.7M
|
Health Technology
|
| O: -0.64%
H: 0.23%
C: -1.0%
AZN | $68.73 -0.29% -0.26% 7.1M
|
Health Technology
|
| O: 2.35%
H: 0.62%
C: -0.45%
growing hypertension growth market
BioWorld by Clarivate Explores the New Era of Radiopharmaceuticals and its Emergence as a Novel Cancer Therapy
Published: 2023-04-13 (Crawled : 07:00) - prnewswire.com
NVSEF | $93.6375 -0.49% 6.88% 130
|
Health Technology
|
| O: 1.25%
H: 0.51%
C: 0.51%
CLVT | $6.86 -2.97% 0.0% 5.6M
|
Information
|
| O: 0.89%
H: 2.54%
C: 1.87%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 1.3%
H: 0.56%
C: 0.51%
cancer therapy
Soft contact lens market size to grow by USD 1.74 billion from 2021 to 2026; Growth driven by rise in the number of people with eye disorders - Technavio
Published: 2023-04-06 (Crawled : 07:00) - prnewswire.com
NVSEF | $93.6375 -0.49% 6.88% 130
|
Health Technology
|
| O: 1.0%
H: 0.63%
C: 0.21%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 1.34%
H: 0.23%
C: -0.08%
BHC | $8.63 -1.48% -1.04% 3M
|
Health Technology
|
| O: 0.27%
H: 0.54%
C: -1.48%
eye growth market
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
Published: 2023-03-16 (Crawled : 07:00) - prnewswire.com
NVSEF | $93.6375 -0.49% 6.88% 130
|
Health Technology
|
| O: 1.16%
H: 0.73%
C: 0.73%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 0.18%
H: 0.77%
C: 0.64%
illuccix fda therapy
Optic Nerve Disorder Treatment Market to Reach USD 5.3 Billion, Globally, by 2031 at 4.5% CAGR: Allied Market Research
Published: 2023-02-27 (Crawled : 07:00) - prnewswire.com
PFE A | $25.91 0.19% -0.19% 28M
|
Health Technology
|
| O: -0.74%
H: 0.7%
C: -1.59%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 0.64%
H: 0.01%
C: -0.72%
ABBV | $161.67 -0.38% -0.19% 3.4M
|
Health Technology
|
| O: 0.36%
H: 0.97%
C: 0.67%
treatment research market
Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors
Published: 2023-02-20 (Crawled : 07:00) - globenewswire.com
NVSEF | $93.6375 -0.49% 6.88% 130
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
| Email alert
Add to watchlist
novartis
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA
Published: 2023-02-06 (Crawled : 07:00) - globenewswire.com
NVSEF | $93.6375 -0.49% 6.88% 130
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: -2.93%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: -0.33%
H: 0.15%
C: -0.12%
AMGN | $265.51 -0.66% -0.67% 1.2M
|
Health Technology
|
| O: 0.08%
H: 0.59%
C: -0.62%
fda biosimilar application license
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
Published: 2023-01-30 (Crawled : 07:00) - globenewswire.com
NVSEF | $93.6375 -0.49% 6.88% 130
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 0.65%
H: 0.37%
C: -0.48%
biosimilar chmp positive
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH
Published: 2022-12-08 (Crawled : 07:00) - globenewswire.com
NVSEF | $93.6375 -0.49% 6.88% 130
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: -1.17%
H: 1.09%
C: 1.01%
novartis
Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer
Published: 2022-12-05 (Crawled : 07:00) - globenewswire.com
NVSEF | $93.6375 -0.49% 6.88% 130
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: -0.03%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 0.93%
H: 0.56%
C: 0.14%
novartis cancer prostate cancer
Breast Cancer Therapeutics Market Size to Grow by USD 13.85 Bn, Targeted Therapy to be Largest Revenue-generating Product Segment - Technavio
Published: 2022-10-27 (Crawled : 07:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 510
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: 0.0%
AZNCF | $135.94 -2.12% -4.19% 770
|
Health Technology
|
| O: 1.47%
H: 0.21%
C: -0.7%
NVSEF | $93.6375 -0.49% 6.88% 130
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
VTRS | $11.32 -0.09% -0.09% 3.6M
|
Health Technology
|
| O: 0.1%
H: 0.85%
C: -1.1%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 0.06%
H: 0.44%
C: -0.15%
GSK | $40.5 -0.39% -1.09% 2.7M
|
Health Technology
|
| O: -0.12%
H: 0.47%
C: 0.21%
ABBV | $161.67 -0.38% -0.19% 3.4M
|
Health Technology
|
| O: 0.82%
H: 0.15%
C: -0.17%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
PBYI | $5.35 1.52% 1.5% 270K
|
Health Technology
|
| O: 1.32%
H: 0.43%
C: -3.46%
AZN | $68.73 -0.29% -0.26% 7.1M
|
Health Technology
|
| O: -0.48%
H: 0.56%
C: -0.12%
AMGN | $265.51 -0.66% -0.67% 1.2M
|
Health Technology
|
| O: 0.5%
H: 0.49%
C: -0.29%
breast therapeutics therapy cancer market
Beta-Lactam And Beta-Lactamase Inhibitors Market to grow by USD 9.04 Bn, Pharmaceutical Market to be Parent Market - Technavio
Published: 2022-10-17 (Crawled : 07:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 510
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -3.61%
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: 0.67%
H: 0.0%
C: 0.0%
VTRS | $11.32 -0.09% -0.09% 3.6M
|
Health Technology
|
| O: 1.05%
H: 0.62%
C: -0.41%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: 2.36%
H: 0.23%
C: -0.1%
GSK | $40.5 -0.39% -1.09% 2.7M
|
Health Technology
|
| O: 2.15%
H: 0.67%
C: -0.22%
ABBV | $161.67 -0.38% -0.19% 3.4M
|
Health Technology
|
| O: -0.2%
H: 1.6%
C: 1.23%
ABT | $108.89 -0.2% 0.28% 3.4M
|
Health Technology
|
| O: 1.2%
H: 1.79%
C: 1.37%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.51%
H: 0.95%
C: 0.65%
market
Alpha Glucosidase Inhibitors Market to record USD 567.96 Mn incremental growth -- Driven by increase in awareness of diabetes and growing initiatives
Published: 2022-09-26 (Crawled : 07:00) - prnewswire.com
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: 5.77%
H: 0.0%
C: -2.27%
AZNCF | $135.94 -2.12% -4.19% 770
|
Health Technology
|
| O: -1.15%
H: 0.0%
C: -2.43%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: -2.04%
H: 0.82%
C: 0.2%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -2.29%
H: 0.35%
C: -0.67%
AZN | $68.73 -0.29% -0.26% 7.1M
|
Health Technology
|
| O: -1.52%
H: 0.48%
C: -1.36%
growing diabetes growth market
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
SNGX | $0.47 21.73% 17.38% 130M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.